Maybe you ought just speak for yourself about 'hate the guy'.
The good 'Doctor' has done quite well steering ship 'Ariad' during these past months. Much 'kudos' to him and now he has the bankroll to be a force to reckon with in Bio-Tech land.
On top of that, he has managed to keep many 'key' talented employees on board ship. Must not to be to bad of a 'honcho' to maintain the loyalty, which is what makes good companies evolve into superior.
I guess he wasn't getting offers for what he felt Ponatinib was worth. This does give him a stronger negotiating hand in partnering. If that is still on the table (which IMO is).
News 
Market Data 
Discover 
